Im­muneer­ing cuts neu­ro­science pro­grams to fo­cus on on­col­o­gy, ex­tend cash run­way

Im­muneer­ing has sus­pend­ed its dis­cov­ery-stage neu­ro­science pro­gram and is now fo­cus­ing ex­clu­sive­ly on its on­col­o­gy pipeline in or­der to ex­tend its cash run­way in­to 2024 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER